SGLT2 Inhibitors: From Structure–Effect Relationship to Pharmacological Response
International Journal of Molecular Sciences · 19.07.2025 · 26 (14) · 6937
DOI: 10.3390/ijms26146937 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.07.2025. Verfasst von Teodora Mateoc und 7 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School, Faculty of Medicine, "Victor Babeș" University of Medicine and Pharmacy, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 250 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
SGLT2 inhibitors have become increasingly used due to their effectiveness in improving not only type 2 diabetes but also cardiovascular, renal and hepatic diseases, as well as the obesity found in metabolic syndrome. Starting from the structure of gliflozins, modifications of the carbohydrate part, aglycone, and also the glycosidic bond between them can determine variations in pharmacokinetic and pharmacodynamic properties. SGLT2 inhibitors, in addition to reducing blood glucose levels, improve alterations in lipid metabolism by diverting excessively accumulated lipids in tissues towards mobilization, lipolysis, β-oxidation, ketogenesis and the utilization of ketone bodies. This enhances anti-inflammatory properties by decreasing the levels of some proinflammatory mediators and by modulating some cell signaling pathways. Thus, in this review, the intimate mechanisms by which SGLT2 inhibitors achieve these therapeutic effects in the various conditions belonging to metabolic syndrome and beyond were described, along with the structure–effect relationship with some specific features of each gliflozin. Starting from these findings, further modeling of these molecules may lead to the creation of new therapeutic uses. Further research is needed to broaden the range of indications and also eliminate adverse effects, such as phenomena leading to lower limb amputations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctoral School, Faculty of Medicine, "Victor Babeș" University of Medicine and Pharmacy, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.
- Intensive Care Unit Department, "Pius Brinzeu" County Emergency Hospital, Liviu Rebreanu Blvd. 156, 300723 Timisoara, Romania.
- Department of Biochemistry and Pharmacology, Faculty of Medicine, "Victor Babeș" University of Medicine and Pharmacy, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.
- ANAPATMOL Research Center, "Victor Babeș" University of Medicine and Pharmacy of Timisoara, 2nd Eftimie Murgu, 300041 Timisoara, Romania.
- Department of Cell and Molecular Biology, Faculty of Medicine, "Victor Babeș" University of Medicine and Pharmacy, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.
ORCID-Profile: Roxana Popescu
Zitieren
APA
Mateoc, T., Dumitrascu, A. L., Flangea, C., Puscasiu, D., Vlad, T., Popescu, R., Marina, C., & Vlad, D. C. (2025). SGLT2 Inhibitors: From Structure–Effect Relationship to Pharmacological Response. International Journal of Molecular Sciences, 26(14), 6937. https://doi.org/10.3390/ijms26146937
Vancouver
Mateoc T, Dumitrascu AL, Flangea C, Puscasiu D, Vlad T, Popescu R, et al. SGLT2 Inhibitors: From Structure–Effect Relationship to Pharmacological Response. International Journal of Molecular Sciences. 2025;26(14):6937. doi:10.3390/ijms26146937
BibTeX
@article{Mateoc2025,
author = {Mateoc, Teodora and Dumitrascu, Andrei-Luca and Flangea, Corina and Puscasiu, Daniela and Vlad, Tania and Popescu, Roxana and Marina, Cristina and Vlad, Daliborca-Cristina},
title = {SGLT2 Inhibitors: From Structure–Effect Relationship to Pharmacological Response},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {14},
pages = {6937},
doi = {10.3390/ijms26146937}
}
EUVIMED